Beta Pharma Revenue and Competitors

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Beta Pharma's estimated annual revenue is currently $8.4M per year.(i)
  • Beta Pharma's estimated revenue per employee is $201,000

Employee Data

  • Beta Pharma has 42 Employees.(i)
  • Beta Pharma grew their employee count by 0% last year.

Beta Pharma's People

NameTitleEmail/Phone
1
VP, Research & DevelopmentReveal Email/Phone
2
Executive Director Drug DiscoveryReveal Email/Phone
3
Manager Legal AffairsReveal Email/Phone
4
Human Resources ManagerReveal Email/Phone
5
Technical Consultant, Drug DiscoveryReveal Email/Phone
6
VP/ COOReveal Email/Phone
7
Business Development & Marketing ManagerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M25-11%N/AN/A
#2
$35.8M1788%N/AN/A
#3
$5.4M27-25%N/AN/A
#4
$4180M145161%$550MN/A
#5
$12.5M6215%N/AN/A
#6
$6.7M119-37%$199.6MN/A
#7
$9.4M477%N/AN/A
#8
$10.3M516%N/AN/A
#9
$106.3M52916%N/AN/A
#10
$15.5M7720%N/AN/A
Add Company

What Is Beta Pharma?

Beta Pharma is an emerging specialty pharmaceutical company dedicated to the discovery, development and commercialization of innovative late stage therapies targeting oncology. Our products pipeline is diverse and undergoing rapid development. Beta Pharma Inc. was founded in 1996, at Science Park of Yale, as a contract research organization (named Beta Chemicals Inc.) to provide custom synthesis service for the pharmaceutical and biotechnology R&D community. In May of 2006, our novel EGFR inhibitor, Icotinib, entered into a Phase I clinical trial in China. The SFDA approved Icotinib on June 7, 2011. The global registration of Icotinib is undergoing, with our regional partners worldwide.

keywords:N/A

N/A

Total Funding

42

Number of Employees

$8.4M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.9M422%N/A
#2
$4.9M420%N/A
#3
$8.2M420%N/A
#4
$11M430%N/A
#5
$6.9M43-4%N/A